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blood pressure; renin-angiotensin system; renin; enzyme precursor; mouse knock out RENIN IS AN ASPARTYL PROTEASE that catalyzes the rate-limiting step in the renin-angiotensin system (RAS), a key modulator of fluid volume and blood pressure. Renin is first synthesized as in the juxtaglomerular cells of the kidney as an enzymatically inactive precursor, prorenin. While prorenin can be reversibly activated in vitro by prolonged exposure to either cold or acid, in juxtaglomerular cells it is irreversibly converted to renin by the proteolytic removal of an amino-terminal prosegment after its entry into dense core secretory granules (28) . The juxtaglomerular cells release both prorenin and renin, and although a number of tissues have the capacity to release prorenin, active renin in the plasma comes almost entirely from the kidneys (2, 10, 24) . Unlike some other aspartyl proteases, the proteolytic activation of prorenin is not autocatalytic (4) but rather requires the action of another protease referred to as the prorenin processing enzyme (PPE). Conclusive identification of the PPE might provide a new target to inhibit the rate-limiting step in the RAS and thereby offer a new treatment for cardiovascular disease.
The identity of the PPE has been difficult to confirm because several proteases with different cleavage preferences can activate prorenin in vitro (23) , suggesting that there is some flexibility in the choice of the cleavage site. Indeed, the prosegment is held to the body of renin by amino acids in the first third of its length (18) and any protease cleavage in the prosegment beyond that point would presumably result in the activation prorenin. Cathepsin B (CTSB) has emerged as the leading candidate for the PPE for several reasons. First, PPE activity purified from whole tissue preparations of human kidney was identified as CTSB (16, 31) . Second, both in vitro and in transfected tissue culture cells, CTSB cleaves human prorenin at the site identified for active renin purified from whole kidney extracts (13, 19) . Finally, CTSB colocalizes with prorenin in the granules of juxtaglomerular cells in rats and mice (17, 27) .
In the present study, we have tested for the ability of CTSB-deficient mice to generate active renin. Our results show that by all of the means tested, the capacity and cell biology of active renin production is identical between CTSBϪ/Ϫ and control mice. As such, our results do not support CTSB as the PPE in the mouse.
MATERIALS AND METHODS
Animals. The mice used in this study were housed in a 10:14-h light-dark cycle with free access to normal mouse chow and water. All of the experiments described herein were approved by the Institutional Animal Ethics Committee of the Clinical Research Institute of Montreal, Montreal, Canada and are in compliance with guidelines issued by the Canadian Council on Animal Care. The inactivation of CTSB was originally carried out in ES cells derived from the 129 strain (5), and CTSB-targeted mice were backcrossed onto the C57BL6 strain at the Northwestern University Feinberg School of Medicine, Chicago, IL for Ͼ 10 generations. CTSB-targeted C57BL6 mice were maintained in the homozygous state (CTSBϪ/Ϫ) by interbreeding and were compared with commercially obtained C57BL6/N (Harlan Teklad, Lachine, QC, Canada). Mice deficient for angiotensinogen (AGTϪ/Ϫ) were a gift from Dr. Oliver Smithies (University of North Carolina, Chapel Hill, NC) and were backcrossed to the FVB/N strain for Ͼ14 generations at the Clinical Research Institute of Montreal, Montreal, Canada. Genotypes were verified by PCR analysis of DNA obtained by tail biopsies. All animals studied were males at 8 -12 wk of age unless otherwise noted. The angiotensin converting enzyme (ACE) inhibitor captopril (Sigma-Aldrich, Oakville, ON, Canada) was administered at a dose of 10 mg·kg Ϫ1 ·day Ϫ1 in drinking water for 5 days. Chloroquine diphosphate (Sigma-Aldrich) was suspended in 5% gum Arabic and administered by gavage at a dose of 10 mg/kg once per day for two consecutive days. Mice were killed 24 h after the last treatment.
Determination of plasma renin concentration. Renin activity was determined by the ANG I generation assay. Sixty microliters of blood was collected by retroorbital puncture using a heparinized microhematocrit capillary pipette (Fisher Scientific, Pittsburgh, PA) from mice that had been lightly anesthetized with ether. EDTA was added to a final concentration of 15 mM, and the plasma fraction was separated immediately by centrifugation. Plasma renin concentration was measured by diluting plasma from untreated (1:100) and captopril-treated (1:1,000) mice in 100 l of buffer containing 0.1 M potassium phosphate (pH 7.4), 0.1 M malic acid (pH 6.5), 0.1 M NaCl, 0.25% BSA, 0.02% NaN3, 3 mM EDTA, 0.03% 8-hydroxyquinoline, and 0.5 mM phenylmethylsulfanyl fluoride. Five microliters of nephrectomized sheep serum containing an excess of AGT (equivalent to 1,000 pg ANG I) were added, and the samples were incubated for 1 h at 37°C. The ANG I generated was quantified by radioimmunoassay.
Microscopy. Excised kidneys were fixed in Bouin's fixative and imbedded in paraffin. Slide-mounted sections were stained with hematoxilyn and eosin for gross histological examination. For immunohistochemistry, deparaffinized sections were incubated with a rabbit polyclonal antirecombinant human renin/prorenin antiserum (BRI-6, 1:200 dilution). Immune complexes were detected with peroxidasecoupled anti-rabbit IgG (Amersham Biosciences) and revealed by 3,3=-diaminobenzidine (Sigma-Aldrich). Sections were photographed without counterstaining using Nomarski optics.
For electron microscopy, minced kidney cortex was rinsed in PBS and fixed for 3 h in 0.1 M sodium cacodylate (pH 7.1) containing 2% glutaraldehyde. Samples were postfixed for 1 h in cacodylate buffer containing 2% osmium tetroxide and were included in Araldite resin (Ladd Research Industries, Burlington, VT) after dehydration. Sections (90 nm) were mounted on copper grids, counterstained with uranyl acetate and lead citrate and were examined in a Joel JEM 1200 EX microscope.
Immunoprecipitation of renal renin. Mice were killed by CO 2 inhalation. The kidneys were immediately removed and decapsulated, and the papilla were cut away. The cortices were cut into 1-to 2-mm blocks and pressed through a 150-m nylon screen by using a rubber policeman. The cortical tissue suspension was lysed by addition of SDS (0.1% final) and spun at 13,000 rpm in a microfuge for 10 min at 4°C to pellet cellular debris and DNA. Nonidet P-40 (Fluka Biochemika, Buchs, Switzerland) was added to a final concentration of 1% and sheep anti-rat prorenin/renin antibody immobilized on Sepharose (10 l/ml of lysate; Molecular Innovations, Novi, Michigan) was added to capture prorenin and renin. After extensive washing, the antiprorenin/renin resin was boiled in SDS-PAGE sample buffer and separated by electrophoresis under reducing conditions. The contents of the gel were transferred onto a nitrocellulose membrane, and the prorenin and renin were revealed by incubation with a rabbit anti-human recombinant prorenin/renin antibody (BRI-6, 1:10,000 dilution). Immune complexes were detected by incubation with an anti-rabbit secondary antibody coupled to peroxidase (NA 934V; Amersham Biosciences) followed by a luminescence assay (Amersham ECL Advance; GE Healthcare, Buckinghamshire, UK) according to the manufacturer's instructions. The specificity of the antibodies used was verified by Western blot analysis using recombinant mouse Ren-1 prorenin.
Statistical analysis. Statistical analysis was performed using GraphPad Prism version 5.0 for Windows, (GraphPad Software, San Diego, CA) using one-way ANOVA with Bonferroni's multiple comparison posttest. Results were considered significant when P Ͻ 0.05.
RESULTS
CTSBϪ/Ϫ mice are viable and produce active renin. CTSBdeficient mice were maintained in the C57BL6 background in the homozygous state (CTSBϪ/Ϫ). Mice were viable and in apparent good health. None of the renal abnormalities ( Fig. 1 ) and preweaning mortality previously reported for mice in the C57BL6 strain that were deficient for components of the renin-angiotensin pathway (reviewed in Ref. 20) were seen.
To test the role of CTSB as a PPE, we compared the levels of active renin in the plasma of control and CTSB-deficient mice both before and after treatment of the mice with the ACE inhibitor, captopril, for 5 days. (Fig. 2) . Because renin production is under tonic feedback inhibition by both blood pressure and ANG II (the peptide product of the RAS), inhibitors of the RAS, such as captopril, lead to an increase in the secretion of active renin (8) . Our results show that control and CTSBϪ/Ϫ mice have comparable levels of active renin. Moreover, following ACE inhibitor treatment, the levels of active renin in the plasma increase more than 15-fold in both control and CTSBϪ/Ϫ mice (Fig. 2) . Thus, the CTSBϪ/Ϫ mice have normal levels of active renin that can be greatly induced by pharmacologic treatment.
Biochemical characterization of renal renin. To test the possibility that CTSBϪ/Ϫ mice produce active renin using an alternative protease, we compared the electrophoretic mobility of renin and prorenin immunopurified from the renal cortex of control and CTSBϪ/Ϫ mice either before or after captopril treatment (Fig. 3A) . Both renin and prorenin can be detected in lysates of kidney cortex by Western blot analysis. After captopril treatment, the relative abundance of prorenin in the kidney increases significantly. Notably, there is no difference in the apparent molecular weight of the active renin extracted from control and CTSBϪ/Ϫ mouse kidney.
Chloroquine is a weak base that concentrates in lysosomes where it alkalinizes this organelle. To test whether the processing of prorenin in the lysosome-like juxtaglomerular cell secretory granules required the activity of an acidic protease, control mice were treated with choloroquine at a dose that exceeds that used clinically for malaria prophylaxis. On the Note that the AGTϪ/Ϫ mouse, which has a complete inactivation of the renin-angiotensin system, develops a severe hydronephrosis, hypertrophy of interlobular arteries (arrows), and has a disorganized tubular distribution in the remaining cortex. FVB/N mice are used for illustration because the AGTϪ/Ϫ mutation is lethal in the C57BL/6 background at this age.
third day after initiation of treatment, the mice were killed, and the renin/prorenin in the kidney was immunoprecipitated and characterized by Western blot analysis (Fig. 3B) . The kidneys of both treated and untreated animals contained primarily active renin, and there was no detectable difference in the migration of these by SDS-PAGE. Thus, choloroquine treatment does not affect the processing of prorenin.
Histomorphology. To verify that renin secretion remains restricted to the juxtaglomerular apparatus in the CTSBϪ/Ϫ mouse, we analyzed the distribution of renin/prorenin staining in the renal cortex of untreated and captopril-treated mice (Fig. 4) . In both the control and CTSB-deficient mice, antibody to prorenin/renin stained cells at the base of glomeruli, the expected location for juxtaglomerular cells. As previously reported (8), captopril treatment resulted in the apparent recruitment of new cells staining for prorenin/renin along the afferent arteriole, as well as a more diffuse staining of cells in the proximal tubules. There were no apparent differences in the pattern of staining seen between control and CTSBϪ/Ϫ mice. Ultrastructural analysis of kidneys from 5-day-old mice also revealed the presence of typical granulated juxtaglomerular cells in CTSBϪ/Ϫ mice that was indistinguishable from those seen in control mice (T. L. Reudelhuber, unpublished observations).
DISCUSSION
The major finding of the present study is that mice deficient for CTSB are not hindered in their capacity to produce active renin. We undertook this study in the C57BL/6N strain because these mice have only one renin gene (Ren-1c). The genomes of many strains of laboratory mice contain two renin genes (Ren-1 and Ren-2) which display differences in their tissue pattern of expression and their protease sensitivity (25) . For this reason, the presence of active renin in many knockout mouse models derived from 129sv ES cells (derived from a 2-renin gene strain of mice) greatly complicates the identification of the PPE. In addition to the measurement of renin activity, we tested phenotypes that are symptomatic of deficiency in active renin production: both pharmacologic inhibition of the RAS during pregnancy as well as the genetic inactivation of the RAS results in severe postnatal renal defects and high rates of preweaning mortality (20) , neither of which were seen in CTSB-deficient mice. Since renin catalyzes the rate-limiting step in the RAS, one might expect to see such symptoms if the PPE is missing.
Although it is formally possible that the processing prorenin function of CTSB had been compensated by another protease with similar activity, CTSBϪ/Ϫ mice are able to muster a large increase in renin production in response to captopril treatment, and the apparent molecular weight of the active renin in CTSBϪ/Ϫ mice is identical to that in the control strain. Moreover, the distribution of cells that produce renin (juxtaglomerular cells) as well as the ultrastructure (not shown) of the nascent granules in which the processing occurs are identical in control and CTSBϪ/Ϫ. Altogether, it seems highly unlikely that another protease is compensating for the CTSB deficiency in our mice. As such, CTSB does not appear to be the PPE in the mouse.
An important question arising from this study is whether the PPE in mouse could be different from that in other species (such as rats and humans). Although the NH 2 -terminus of mouse renal renin has not been reported, Jones et al. (12) found that mouse Ren-1 renin produced in an engineered kidney tumor cell line (As4.1) began at the analogous position to that reported for rat kidney renin (3) that is seven amino acids downstream from the site reported for human renin purified from kidney extracts (6) and cleaved in human prorenin by Fig. 2 . Active renin concentrations in control and CTSBϪ/Ϫ mice. Renin activity was measured in plasma either untreated or after 7 days of treatment with the angiotensin converting enzyme inhibitor (ACE I) captopril. AI, angiotensin I. N ϭ 7-9 animals per group. ***P Ͻ 0.001 compared with nontreated mice in the same group. CTSB in vitro (13, 19) (Fig. 5) . One possible explanation is that human, mouse, and rat prorenin are all initially cleaved by CTSB, but the mouse and rat renins are subsequently "trimmed" by other enzymes to generate a different amino terminus. Alternatively, different PPEs might activate human prorenin and the prorenins of rat and mouse. However, insertion of the human renin gene (with its own gene control elements) into the genome of either rats or mice results in the production of active human renin from the kidneys of the transgenic animals (1, 26, 32) , although the cleavage site of this renin has never been reported. In contrast, engineered expression of human renin from the liver of transgenic mice, a CTSB-rich tissue, results in the release exclusively of unprocessed human prorenin into the circulation (22) . Taken together, these results suggest that mice and rats restrict the production of active renin to the juxtaglomerular cells of the kidney and that these cells produce a PPE that is active on mouse, rat, and human prorenins.
Another possibility is that despite its colocalization with prorenin and its ability to cleave prorenin in vitro, CTSB is not the PPE in juxtaglomerular cells. Juxtaglomerular cell granules are, in fact, secretory lysosomes as evidenced by the aberrant juxtaglomerular cell granules in Beige mice, which have mutation that leads to a lysosomal secretory defect (11) . Secretory lysosomes in other cell types, such as osteoclasts and cells of the immune system, serve degradative roles (reviewed in Ref.
9). The fact that release of renin from juxtaglomerular cells is not accompanied by the degradative activity is consistent with the possibility that the CTSB is inactivated in juxtaglomerular cell granules by cystatins (reviewed in Ref. 7) or other mechanisms. The generation of whole tissue extracts (31) or the overexpression of CTSB and prorenin in tissue culture cells (13, 19) could conceivably overcome the CTSB inhibition in juxtaglomerular cell granules. Moreover, the endoprotease activity of CTSB is broadly distributed in the acidic pH range of 4 -6 (14) , and treatment of mice with the lysosomal alkalinizing agent chloroquine did not affect the degree of prorenin processing in the mouse kidneys (Fig. 3B) . Taken together, the current results are not consistent with CTSB being the PPE in mice.
Perspectives and Significance
In the present study, we have provided several lines of evidence that CTSB is not the PPE responsible for the generation of renin in the mouse. More importantly, these results also raise the possibility that the PPE in other mammals, including in humans, where it has been proposed to be CTSB, has yet to be identified. Identification of the PPE has been complicated by the tendency of isolated juxtaglomerular cells to produce only prorenin (15, 21) . It is not clear whether this phenomenon is due to a rapid de-differentiation of the juxtaglomerular cell upon isolation or whether these cells normally take up the PPE from the interstitial space and redirect it to the lysosome-like granules where it activates prorenin. Indeed, juxtaglomerular cells in situ have a strong propensity for taking up a variety of molecules from fluorochromes to circulating proteins (29, 30) . Because circulating renin catalyzes the ratelimiting step in the biosynthesis of the potent vasoactive peptide ANG II, the PPE could constitute a novel and important clinical target in inhibiting the activity of the reninangiotensin system. 
